scholarly journals Exploring Modality Compatibility in the Response-Effect Compatibility Paradigm

2017 ◽  
Vol 13 (1) ◽  
pp. 97-104 ◽  
Author(s):  
Noémi Földes ◽  
Andrea M. Philipp ◽  
Arnaud Badets ◽  
Iring Koch
Author(s):  
Erik Friedgen ◽  
Iring Koch ◽  
Denise Nadine Stephan

Abstract Modality compatibility denotes the match between sensory stimulus modality and the sensory modality of the anticipated response effect (for example, vocal responses usually lead to auditory effects, so that auditory–vocal stimulus–response mappings are modality-compatible, whereas visual–vocal mappings are modality incompatible). In task switching studies, it has been found that switching between two modality-incompatible mappings (auditory-manual and visual–vocal) resulted in higher switch costs than switching between two modality-compatible mappings (auditory–vocal and visual-manual). This finding suggests that with modality-incompatible mappings, the anticipation of the effect of each response primes the stimulus modality linked to the competing task, creating task confusion. In Experiment 1, we examined whether modality-compatibility effects in task switching are increased by strengthening the auditory–vocal coupling using spatial-verbal stimuli relative to spatial-location stimuli. In Experiment 2, we aimed at achieving the same goal by requiring temporal stimulus discrimination relative to spatial stimulus localisation. Results suggest that both spatial-verbal stimuli and temporal discrimination can increase modality-specific task interference through a variation of the strength of anticipation in the response-effect coupling. This provides further support for modality specificity of cognitive control processes in task switching.


2013 ◽  
Author(s):  
Denise Nadine Stephan ◽  
Iring Koch ◽  
Jessica Hendler ◽  
Lynn Huestegge

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
B. Herman ◽  
F. Mandel

Objective:There appears to be no dose-response effect for pregabalin at doses of 300-600 mg, and a modest dose-response effect in the range of 150-300 mg. The goal of the current investigation was to determine the effect of the starting dose on the speed of onset of anxiolytic efficacy.Methods:Data were analyzed from 7 trials of outpatients with DSM-IV GAD and a HAM-A total score ≥18. Starting doses of pregabalin ranged from 100 mg (N=301) or 150 mg (N=104), to 200 mg (N=167) and 300 mg (N=388). Assessment of early improvement included the HAM-A total score and CGI-Severity and Improvement scores.Results:The mean Week 1 HAM-A change score was similar for a starting dose of 200 mg/d with no titration (-8.24) when compared to patients who started on 200 mg/d and then titrated up to 400 mg/d on Day 4 (-8.64). The mean Week 1 HAM-A change score was somewhat higher for patients started on 300 mg/d, and then titrated to 450 mg/d on Day 4/5 (-8.84) when compared to patients started on a lower (100/150 mg/d) dose and titrated on Day 5 to 400/450 mg/d (-7.32). Starting on a dose of 300 mg/d with no titration resulted in an intermediate Week 1 change score (-7.87). The interaction of starting dose and titration schedule with baseline anxiety severity will be summarized in detail.Conclusion:The initial dose of pregabalin appears to have only a weak effect on the speed of onset of anxiolytic improvement.


2017 ◽  
Vol 94 ◽  
pp. 110-111
Author(s):  
Lei Guo ◽  
Yi-Xi Chen ◽  
Yu-Ting Hu ◽  
Xue-Yan Wu ◽  
Yang He ◽  
...  

1990 ◽  
Vol 46 (4) ◽  
pp. 664-668 ◽  
Author(s):  
Subhkij Angsubhakorn ◽  
Panisa Get-Ngern ◽  
Makoto Miyamoto ◽  
Natth Bhamarapravati

Science ◽  
1980 ◽  
Vol 210 (4473) ◽  
pp. 1043-1043
Author(s):  
William M. Lewis ◽  
Michael C. Grant

Sign in / Sign up

Export Citation Format

Share Document